Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Alternative Dosing Rate in NHL
NCT00719472Phase 3Completed
- Sponsor
- Genentech
- Start
- Jul 2008
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Genentech. Started Jul 2008; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00719472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719472.